Asenapine Transdermal Patch for the Management of Schizophrenia.
SZ
antipsychotic
asenapine
psychosis
secuado
sublingual
transdermal patch
Journal
Psychopharmacology bulletin
ISSN: 2472-2448
Titre abrégé: Psychopharmacol Bull
Pays: United States
ID NLM: 0101123
Informations de publication
Date de publication:
14 09 2020
14 09 2020
Historique:
entrez:
5
10
2020
pubmed:
6
10
2020
medline:
15
12
2021
Statut:
ppublish
Résumé
This is a comprehensive review of the literature regarding the use of asenapine for the treatment of schizophrenia (SZ) in adults. It covers an introduction, epidemiology, risk factors, pathophysiology, and current treatment modalities regarding SZ, provides a background on the mechanism of action of asenapine, and then reviews the existing evidence for use of asenapine in both its sublingual and transdermal formulation in the treatment of SZ. SZ is a complex and multifactorial mental disorder which is thought to combine several genetic, epigenetic, and environmental factors causing abnormalities in the dopaminergic system. Symptoms are categorized in delusions, hallucinations, disorganization, and negative presentations like affective flattening and apathy. Current treatment focuses on antipsychotic medications by means of oral administration or long-acting injection. Asenapine is a second-generation antipsychotic with 5HT-2A antagonist and 5HT-1A/1B partial agonist properties, which provides a favorable profile in targeting schizophrenic symptoms, while reducing motor side effects and improving mood and cognition. Asenapine in its sublingual formulation was FDA approved for treatment of SZ and bipolar I disorder in adults in August of 2009 and has been proven to be both effective and safe. Transdermal patch of asenapine (Secuado) was FDA approved in October of 2019, the first and only FDA approved patch for SZ in adults, which offers another strategy for treatment to improve compliance and ease of administration. SZ is a chronic and debilitating disease which is still not well understood and comes at great cost with regards to the quality of life for patients. Medication side-effects and compliance are enormous issues which take a toll on health care systems in industrialized nations and keep patients from achieving stability with their disease. Transdermal asenapine is a new first-in-class dosage form and provides a novel modality of administration. It has been shown to be effective in reducing positive, as well as negative symptoms, while still maintaining a favorable side-effect profile.
Substances chimiques
Antipsychotic Agents
0
Dibenzocycloheptenes
0
Heterocyclic Compounds, 4 or More Rings
0
asenapine
JKZ19V908O
Types de publication
Case Reports
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
60-82Informations de copyright
Copyright © 1964–2019 by MedWorks Media Inc, Los Angeles, CA All rights reserved. Printed in the United States.
Références
J Clin Psychiatry. 2012 Dec;73(12):1533-40
pubmed: 23290326
Psychopharmacology (Berl). 2009 Jun;204(2):251-64
pubmed: 19198810
Neurosci Biobehav Rev. 2020 Sep;116:74-88
pubmed: 32533996
Schizophr Bull. 2013 Sep;39(5):960-1
pubmed: 23861538
Molecules. 2018 Aug 20;23(8):
pubmed: 30127324
Biol Psychiatry. 2017 Jan 1;81(1):9-20
pubmed: 27720198
Psychopharmacology (Berl). 2009 Nov;206(4):699-714
pubmed: 19462162
Am J Geriatr Psychiatry. 2020 Jan;28(1):23-30
pubmed: 31481273
Schizophr Res. 2013 Nov;150(2-3):442-9
pubmed: 24075603
Clin Ther. 2012 May;34(5):1023-40
pubmed: 22494521
Can J Psychiatry. 2017 Feb;62(2):123-137
pubmed: 27481921
Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509
pubmed: 23545936
Can J Psychiatry. 2019 Jan;64(1):5-17
pubmed: 29742910
Epidemiol Rev. 2008;30:67-76
pubmed: 18480098
Cochrane Database Syst Rev. 2015 Nov 24;(11):CD011458
pubmed: 26599405
Transl Psychiatry. 2018 Jan 31;8(1):30
pubmed: 29382821
P T. 2014 Sep;39(9):638-45
pubmed: 25210417
BMJ. 2011 Mar 01;342:d738
pubmed: 21363868
Pharmacopsychiatry. 2010 Jun;43(4):138-46
pubmed: 20205074
Schizophr Res. 2020 Nov;225:4-14
pubmed: 31806527
J Clin Psychiatry. 2019 Jul 16;80(4):
pubmed: 31318185
Asian J Psychiatr. 2019 Aug;44:200-208
pubmed: 31419737
Eur Neuropsychopharmacol. 2015 Apr;25(4):531-43
pubmed: 25656272
Schizophr Bull. 2015 Nov;41(6):1220-2
pubmed: 26392626
Neuropsychopharmacology. 2008 Nov;33(12):2934-45
pubmed: 18418367
Schizophr Bull. 1989;15(3):453-64
pubmed: 2683041
Trends Mol Med. 2016 Mar;22(3):242-253
pubmed: 26869297
Lancet. 2009 Aug 22;374(9690):635-45
pubmed: 19700006
Sci Rep. 2019 Jul 8;9(1):9865
pubmed: 31285487
JAMA Psychiatry. 2017 Jul 1;74(7):686-693
pubmed: 28593216